The Scientist Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology
3/5/12
Reply
(1)
•!Report Abuse
View all 1 replies
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
The Scientist
More on ABT by The Scientist